

Global Therapeutic Antibodies Drug Market 2023 by Company, Regions, Type and Application, Forecast to 2029

<https://marketpublishers.com/r/G8956600C324EN.html>

Date: November 2023

Pages: 128

Price: US\$ 3,480.00 (Single User License)

ID: G8956600C324EN

Abstracts

According to our (Global Info Research) latest study, the global Therapeutic Antibodies Drug market size was valued at USD 180490 million in 2022 and is forecast to a readjusted size of USD 363690 million by 2029 with a CAGR of 10.5% during review period.

Therapeutic antibodies are drugs that use antibodies, one of the main players in our immune system inherent in our body. By making use of the specificity by which each antibody recognizes only one antigen, pinpointed attacks on specific antigens are possible.

The Therapeutic Antibodies Drug Market is driven by the remarkable potential of therapeutic antibodies to treat a diverse array of diseases, from cancer and autoimmune disorders to infectious diseases. Monoclonal antibodies have gained prominence as highly targeted and effective therapeutic agents that can modulate the immune system, neutralize pathogens, and inhibit disease-associated proteins. As precision medicine and biopharmaceutical innovations continue to advance, the demand for therapeutic antibodies grows. Innovations in antibody design, engineering, and manufacturing technologies further contribute to market expansion. Nevertheless, a significant challenge for this market is the need to address high production costs, optimize therapeutic antibody development processes, and navigate complex regulatory pathways while ensuring accessibility and affordability for patients. Overcoming manufacturing complexities, managing research and development costs, and addressing regulatory standards are ongoing challenges. Additionally, the market faces competition from small molecules and other biologic therapies, necessitating continuous research and development efforts to unlock the full therapeutic potential of therapeutic

antibodies. Striking a balance between providing safe, effective, and accessible therapeutic antibody drugs while addressing scientific and regulatory challenges is essential for the continued growth of the Therapeutic Antibodies Drug Market.

The Global Info Research report includes an overview of the development of the Therapeutic Antibodies Drug industry chain, the market status of Immune Diseases (Monoclonal Antibodies, Bi-Specific Antibodies Therapy), Cancer (Monoclonal Antibodies, Bi-Specific Antibodies Therapy), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Therapeutic Antibodies Drug.

Regionally, the report analyzes the Therapeutic Antibodies Drug markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Therapeutic Antibodies Drug market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:

The report presents comprehensive understanding of the Therapeutic Antibodies Drug market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Therapeutic Antibodies Drug industry.

The report involves analyzing the market at a macro level:

Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Monoclonal Antibodies, Bi-Specific Antibodies Therapy).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Therapeutic Antibodies Drug market.

Regional Analysis: The report involves examining the Therapeutic Antibodies Drug market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Therapeutic Antibodies Drug market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Therapeutic Antibodies Drug:

Company Analysis: Report covers individual Therapeutic Antibodies Drug players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Therapeutic Antibodies Drug. This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Immune Diseases, Cancer).

Technology Analysis: Report covers specific technologies relevant to Therapeutic Antibodies Drug. It assesses the current state, advancements, and potential future developments in Therapeutic Antibodies Drug areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report presents insights into the competitive landscape of the Therapeutic Antibodies Drug market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation

Therapeutic Antibodies Drug market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.

Market segment by Type

Monoclonal Antibodies

Bi-Specific Antibodies Therapy

Antibody-drug Conjugates

Other

Market segment by Application

Immune Diseases

Cancer

Other

Market segment by players, this report covers

AbbVie

Johnson & Johnson

Novartis

Gilead Sciences

Roche

Bristol-Myers Squibb

Amgen

AstraZeneca

Merck & Co

Takeda

Merck KGaA

Seagen

Eli Lilly

Ono Pharmaceutical

Pfizer

Regeneron

Innovent

Hengrui Medicine

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)

South America (Brazil, Argentina and Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Therapeutic Antibodies Drug product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Therapeutic Antibodies Drug, with revenue, gross margin and global market share of Therapeutic Antibodies Drug from 2018 to 2023.

Chapter 3, the Therapeutic Antibodies Drug competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023. and Therapeutic Antibodies Drug market forecast, by regions, type and application, with consumption value, from 2024 to 2029.

Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Therapeutic Antibodies Drug.

Chapter 13, to describe Therapeutic Antibodies Drug research findings and conclusion.

Contents

1 MARKET OVERVIEW

- 1.1 Product Overview and Scope of Therapeutic Antibodies Drug
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Classification of Therapeutic Antibodies Drug by Type
 - 1.3.1 Overview: Global Therapeutic Antibodies Drug Market Size by Type: 2018 Versus 2022 Versus 2029
 - 1.3.2 Global Therapeutic Antibodies Drug Consumption Value Market Share by Type in 2022
 - 1.3.3 Monoclonal Antibodies
 - 1.3.4 Bi-Specific Antibodies Therapy
 - 1.3.5 Antibody-drug Conjugates
 - 1.3.6 Other
- 1.4 Global Therapeutic Antibodies Drug Market by Application
 - 1.4.1 Overview: Global Therapeutic Antibodies Drug Market Size by Application: 2018 Versus 2022 Versus 2029
 - 1.4.2 Immune Diseases
 - 1.4.3 Cancer
 - 1.4.4 Other
- 1.5 Global Therapeutic Antibodies Drug Market Size & Forecast
- 1.6 Global Therapeutic Antibodies Drug Market Size and Forecast by Region
 - 1.6.1 Global Therapeutic Antibodies Drug Market Size by Region: 2018 VS 2022 VS 2029
 - 1.6.2 Global Therapeutic Antibodies Drug Market Size by Region, (2018-2029)
 - 1.6.3 North America Therapeutic Antibodies Drug Market Size and Prospect (2018-2029)
 - 1.6.4 Europe Therapeutic Antibodies Drug Market Size and Prospect (2018-2029)
 - 1.6.5 Asia-Pacific Therapeutic Antibodies Drug Market Size and Prospect (2018-2029)
 - 1.6.6 South America Therapeutic Antibodies Drug Market Size and Prospect (2018-2029)
 - 1.6.7 Middle East and Africa Therapeutic Antibodies Drug Market Size and Prospect (2018-2029)

2 COMPANY PROFILES

- 2.1 AbbVie
 - 2.1.1 AbbVie Details

- 2.1.2 AbbVie Major Business
- 2.1.3 AbbVie Therapeutic Antibodies Drug Product and Solutions
- 2.1.4 AbbVie Therapeutic Antibodies Drug Revenue, Gross Margin and Market Share (2018-2023)
- 2.1.5 AbbVie Recent Developments and Future Plans
- 2.2 Johnson & Johnson
 - 2.2.1 Johnson & Johnson Details
 - 2.2.2 Johnson & Johnson Major Business
 - 2.2.3 Johnson & Johnson Therapeutic Antibodies Drug Product and Solutions
 - 2.2.4 Johnson & Johnson Therapeutic Antibodies Drug Revenue, Gross Margin and Market Share (2018-2023)
 - 2.2.5 Johnson & Johnson Recent Developments and Future Plans
- 2.3 Novartis
 - 2.3.1 Novartis Details
 - 2.3.2 Novartis Major Business
 - 2.3.3 Novartis Therapeutic Antibodies Drug Product and Solutions
 - 2.3.4 Novartis Therapeutic Antibodies Drug Revenue, Gross Margin and Market Share (2018-2023)
 - 2.3.5 Novartis Recent Developments and Future Plans
- 2.4 Gilead Sciences
 - 2.4.1 Gilead Sciences Details
 - 2.4.2 Gilead Sciences Major Business
 - 2.4.3 Gilead Sciences Therapeutic Antibodies Drug Product and Solutions
 - 2.4.4 Gilead Sciences Therapeutic Antibodies Drug Revenue, Gross Margin and Market Share (2018-2023)
 - 2.4.5 Gilead Sciences Recent Developments and Future Plans
- 2.5 Roche
 - 2.5.1 Roche Details
 - 2.5.2 Roche Major Business
 - 2.5.3 Roche Therapeutic Antibodies Drug Product and Solutions
 - 2.5.4 Roche Therapeutic Antibodies Drug Revenue, Gross Margin and Market Share (2018-2023)
 - 2.5.5 Roche Recent Developments and Future Plans
- 2.6 Bristol-Myers Squibb
 - 2.6.1 Bristol-Myers Squibb Details
 - 2.6.2 Bristol-Myers Squibb Major Business
 - 2.6.3 Bristol-Myers Squibb Therapeutic Antibodies Drug Product and Solutions
 - 2.6.4 Bristol-Myers Squibb Therapeutic Antibodies Drug Revenue, Gross Margin and Market Share (2018-2023)

- 2.6.5 Bristol-Myers Squibb Recent Developments and Future Plans
- 2.7 Amgen
 - 2.7.1 Amgen Details
 - 2.7.2 Amgen Major Business
 - 2.7.3 Amgen Therapeutic Antibodies Drug Product and Solutions
 - 2.7.4 Amgen Therapeutic Antibodies Drug Revenue, Gross Margin and Market Share (2018-2023)
 - 2.7.5 Amgen Recent Developments and Future Plans
- 2.8 AstraZeneca
 - 2.8.1 AstraZeneca Details
 - 2.8.2 AstraZeneca Major Business
 - 2.8.3 AstraZeneca Therapeutic Antibodies Drug Product and Solutions
 - 2.8.4 AstraZeneca Therapeutic Antibodies Drug Revenue, Gross Margin and Market Share (2018-2023)
 - 2.8.5 AstraZeneca Recent Developments and Future Plans
- 2.9 Merck & Co
 - 2.9.1 Merck & Co Details
 - 2.9.2 Merck & Co Major Business
 - 2.9.3 Merck & Co Therapeutic Antibodies Drug Product and Solutions
 - 2.9.4 Merck & Co Therapeutic Antibodies Drug Revenue, Gross Margin and Market Share (2018-2023)
 - 2.9.5 Merck & Co Recent Developments and Future Plans
- 2.10 Takeda
 - 2.10.1 Takeda Details
 - 2.10.2 Takeda Major Business
 - 2.10.3 Takeda Therapeutic Antibodies Drug Product and Solutions
 - 2.10.4 Takeda Therapeutic Antibodies Drug Revenue, Gross Margin and Market Share (2018-2023)
 - 2.10.5 Takeda Recent Developments and Future Plans
- 2.11 Merck KGaA
 - 2.11.1 Merck KGaA Details
 - 2.11.2 Merck KGaA Major Business
 - 2.11.3 Merck KGaA Therapeutic Antibodies Drug Product and Solutions
 - 2.11.4 Merck KGaA Therapeutic Antibodies Drug Revenue, Gross Margin and Market Share (2018-2023)
 - 2.11.5 Merck KGaA Recent Developments and Future Plans
- 2.12 Seagen
 - 2.12.1 Seagen Details
 - 2.12.2 Seagen Major Business

- 2.12.3 Seagen Therapeutic Antibodies Drug Product and Solutions
- 2.12.4 Seagen Therapeutic Antibodies Drug Revenue, Gross Margin and Market Share (2018-2023)
- 2.12.5 Seagen Recent Developments and Future Plans
- 2.13 Eli Lilly
 - 2.13.1 Eli Lilly Details
 - 2.13.2 Eli Lilly Major Business
 - 2.13.3 Eli Lilly Therapeutic Antibodies Drug Product and Solutions
 - 2.13.4 Eli Lilly Therapeutic Antibodies Drug Revenue, Gross Margin and Market Share (2018-2023)
 - 2.13.5 Eli Lilly Recent Developments and Future Plans
- 2.14 Ono Pharmaceutical
 - 2.14.1 Ono Pharmaceutical Details
 - 2.14.2 Ono Pharmaceutical Major Business
 - 2.14.3 Ono Pharmaceutical Therapeutic Antibodies Drug Product and Solutions
 - 2.14.4 Ono Pharmaceutical Therapeutic Antibodies Drug Revenue, Gross Margin and Market Share (2018-2023)
 - 2.14.5 Ono Pharmaceutical Recent Developments and Future Plans
- 2.15 Pfizer
 - 2.15.1 Pfizer Details
 - 2.15.2 Pfizer Major Business
 - 2.15.3 Pfizer Therapeutic Antibodies Drug Product and Solutions
 - 2.15.4 Pfizer Therapeutic Antibodies Drug Revenue, Gross Margin and Market Share (2018-2023)
 - 2.15.5 Pfizer Recent Developments and Future Plans
- 2.16 Regeneron
 - 2.16.1 Regeneron Details
 - 2.16.2 Regeneron Major Business
 - 2.16.3 Regeneron Therapeutic Antibodies Drug Product and Solutions
 - 2.16.4 Regeneron Therapeutic Antibodies Drug Revenue, Gross Margin and Market Share (2018-2023)
 - 2.16.5 Regeneron Recent Developments and Future Plans
- 2.17 Innovent
 - 2.17.1 Innovent Details
 - 2.17.2 Innovent Major Business
 - 2.17.3 Innovent Therapeutic Antibodies Drug Product and Solutions
 - 2.17.4 Innovent Therapeutic Antibodies Drug Revenue, Gross Margin and Market Share (2018-2023)
 - 2.17.5 Innovent Recent Developments and Future Plans

2.18 Hengrui Medicine

2.18.1 Hengrui Medicine Details

2.18.2 Hengrui Medicine Major Business

2.18.3 Hengrui Medicine Therapeutic Antibodies Drug Product and Solutions

2.18.4 Hengrui Medicine Therapeutic Antibodies Drug Revenue, Gross Margin and Market Share (2018-2023)

2.18.5 Hengrui Medicine Recent Developments and Future Plans

3 MARKET COMPETITION, BY PLAYERS

3.1 Global Therapeutic Antibodies Drug Revenue and Share by Players (2018-2023)

3.2 Market Share Analysis (2022)

3.2.1 Market Share of Therapeutic Antibodies Drug by Company Revenue

3.2.2 Top 3 Therapeutic Antibodies Drug Players Market Share in 2022

3.2.3 Top 6 Therapeutic Antibodies Drug Players Market Share in 2022

3.3 Therapeutic Antibodies Drug Market: Overall Company Footprint Analysis

3.3.1 Therapeutic Antibodies Drug Market: Region Footprint

3.3.2 Therapeutic Antibodies Drug Market: Company Product Type Footprint

3.3.3 Therapeutic Antibodies Drug Market: Company Product Application Footprint

3.4 New Market Entrants and Barriers to Market Entry

3.5 Mergers, Acquisition, Agreements, and Collaborations

4 MARKET SIZE SEGMENT BY TYPE

4.1 Global Therapeutic Antibodies Drug Consumption Value and Market Share by Type (2018-2023)

4.2 Global Therapeutic Antibodies Drug Market Forecast by Type (2024-2029)

5 MARKET SIZE SEGMENT BY APPLICATION

5.1 Global Therapeutic Antibodies Drug Consumption Value Market Share by Application (2018-2023)

5.2 Global Therapeutic Antibodies Drug Market Forecast by Application (2024-2029)

6 NORTH AMERICA

6.1 North America Therapeutic Antibodies Drug Consumption Value by Type (2018-2029)

6.2 North America Therapeutic Antibodies Drug Consumption Value by Application

(2018-2029)

6.3 North America Therapeutic Antibodies Drug Market Size by Country

6.3.1 North America Therapeutic Antibodies Drug Consumption Value by Country
(2018-2029)

6.3.2 United States Therapeutic Antibodies Drug Market Size and Forecast
(2018-2029)

6.3.3 Canada Therapeutic Antibodies Drug Market Size and Forecast (2018-2029)

6.3.4 Mexico Therapeutic Antibodies Drug Market Size and Forecast (2018-2029)

7 EUROPE

7.1 Europe Therapeutic Antibodies Drug Consumption Value by Type (2018-2029)

7.2 Europe Therapeutic Antibodies Drug Consumption Value by Application
(2018-2029)

7.3 Europe Therapeutic Antibodies Drug Market Size by Country

7.3.1 Europe Therapeutic Antibodies Drug Consumption Value by Country
(2018-2029)

7.3.2 Germany Therapeutic Antibodies Drug Market Size and Forecast (2018-2029)

7.3.3 France Therapeutic Antibodies Drug Market Size and Forecast (2018-2029)

7.3.4 United Kingdom Therapeutic Antibodies Drug Market Size and Forecast
(2018-2029)

7.3.5 Russia Therapeutic Antibodies Drug Market Size and Forecast (2018-2029)

7.3.6 Italy Therapeutic Antibodies Drug Market Size and Forecast (2018-2029)

8 ASIA-PACIFIC

8.1 Asia-Pacific Therapeutic Antibodies Drug Consumption Value by Type (2018-2029)

8.2 Asia-Pacific Therapeutic Antibodies Drug Consumption Value by Application
(2018-2029)

8.3 Asia-Pacific Therapeutic Antibodies Drug Market Size by Region

8.3.1 Asia-Pacific Therapeutic Antibodies Drug Consumption Value by Region
(2018-2029)

8.3.2 China Therapeutic Antibodies Drug Market Size and Forecast (2018-2029)

8.3.3 Japan Therapeutic Antibodies Drug Market Size and Forecast (2018-2029)

8.3.4 South Korea Therapeutic Antibodies Drug Market Size and Forecast (2018-2029)

8.3.5 India Therapeutic Antibodies Drug Market Size and Forecast (2018-2029)

8.3.6 Southeast Asia Therapeutic Antibodies Drug Market Size and Forecast
(2018-2029)

8.3.7 Australia Therapeutic Antibodies Drug Market Size and Forecast (2018-2029)

9 SOUTH AMERICA

- 9.1 South America Therapeutic Antibodies Drug Consumption Value by Type (2018-2029)
- 9.2 South America Therapeutic Antibodies Drug Consumption Value by Application (2018-2029)
- 9.3 South America Therapeutic Antibodies Drug Market Size by Country
 - 9.3.1 South America Therapeutic Antibodies Drug Consumption Value by Country (2018-2029)
 - 9.3.2 Brazil Therapeutic Antibodies Drug Market Size and Forecast (2018-2029)
 - 9.3.3 Argentina Therapeutic Antibodies Drug Market Size and Forecast (2018-2029)

10 MIDDLE EAST & AFRICA

- 10.1 Middle East & Africa Therapeutic Antibodies Drug Consumption Value by Type (2018-2029)
- 10.2 Middle East & Africa Therapeutic Antibodies Drug Consumption Value by Application (2018-2029)
- 10.3 Middle East & Africa Therapeutic Antibodies Drug Market Size by Country
 - 10.3.1 Middle East & Africa Therapeutic Antibodies Drug Consumption Value by Country (2018-2029)
 - 10.3.2 Turkey Therapeutic Antibodies Drug Market Size and Forecast (2018-2029)
 - 10.3.3 Saudi Arabia Therapeutic Antibodies Drug Market Size and Forecast (2018-2029)
 - 10.3.4 UAE Therapeutic Antibodies Drug Market Size and Forecast (2018-2029)

11 MARKET DYNAMICS

- 11.1 Therapeutic Antibodies Drug Market Drivers
- 11.2 Therapeutic Antibodies Drug Market Restraints
- 11.3 Therapeutic Antibodies Drug Trends Analysis
- 11.4 Porters Five Forces Analysis
 - 11.4.1 Threat of New Entrants
 - 11.4.2 Bargaining Power of Suppliers
 - 11.4.3 Bargaining Power of Buyers
 - 11.4.4 Threat of Substitutes
 - 11.4.5 Competitive Rivalry

12 INDUSTRY CHAIN ANALYSIS

- 12.1 Therapeutic Antibodies Drug Industry Chain
- 12.2 Therapeutic Antibodies Drug Upstream Analysis
- 12.3 Therapeutic Antibodies Drug Midstream Analysis
- 12.4 Therapeutic Antibodies Drug Downstream Analysis

13 RESEARCH FINDINGS AND CONCLUSION

14 APPENDIX

- 14.1 Methodology
- 14.2 Research Process and Data Source
- 14.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global Therapeutic Antibodies Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029

Table 2. Global Therapeutic Antibodies Drug Consumption Value by Application, (USD Million), 2018 & 2022 & 2029

Table 3. Global Therapeutic Antibodies Drug Consumption Value by Region (2018-2023) & (USD Million)

Table 4. Global Therapeutic Antibodies Drug Consumption Value by Region (2024-2029) & (USD Million)

Table 5. AbbVie Company Information, Head Office, and Major Competitors

Table 6. AbbVie Major Business

Table 7. AbbVie Therapeutic Antibodies Drug Product and Solutions

Table 8. AbbVie Therapeutic Antibodies Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 9. AbbVie Recent Developments and Future Plans

Table 10. Johnson & Johnson Company Information, Head Office, and Major Competitors

Table 11. Johnson & Johnson Major Business

Table 12. Johnson & Johnson Therapeutic Antibodies Drug Product and Solutions

Table 13. Johnson & Johnson Therapeutic Antibodies Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 14. Johnson & Johnson Recent Developments and Future Plans

Table 15. Novartis Company Information, Head Office, and Major Competitors

Table 16. Novartis Major Business

Table 17. Novartis Therapeutic Antibodies Drug Product and Solutions

Table 18. Novartis Therapeutic Antibodies Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 19. Novartis Recent Developments and Future Plans

Table 20. Gilead Sciences Company Information, Head Office, and Major Competitors

Table 21. Gilead Sciences Major Business

Table 22. Gilead Sciences Therapeutic Antibodies Drug Product and Solutions

Table 23. Gilead Sciences Therapeutic Antibodies Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 24. Gilead Sciences Recent Developments and Future Plans

Table 25. Roche Company Information, Head Office, and Major Competitors

Table 26. Roche Major Business

- Table 27. Roche Therapeutic Antibodies Drug Product and Solutions
- Table 28. Roche Therapeutic Antibodies Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 29. Roche Recent Developments and Future Plans
- Table 30. Bristol-Myers Squibb Company Information, Head Office, and Major Competitors
- Table 31. Bristol-Myers Squibb Major Business
- Table 32. Bristol-Myers Squibb Therapeutic Antibodies Drug Product and Solutions
- Table 33. Bristol-Myers Squibb Therapeutic Antibodies Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 34. Bristol-Myers Squibb Recent Developments and Future Plans
- Table 35. Amgen Company Information, Head Office, and Major Competitors
- Table 36. Amgen Major Business
- Table 37. Amgen Therapeutic Antibodies Drug Product and Solutions
- Table 38. Amgen Therapeutic Antibodies Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 39. Amgen Recent Developments and Future Plans
- Table 40. AstraZeneca Company Information, Head Office, and Major Competitors
- Table 41. AstraZeneca Major Business
- Table 42. AstraZeneca Therapeutic Antibodies Drug Product and Solutions
- Table 43. AstraZeneca Therapeutic Antibodies Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 44. AstraZeneca Recent Developments and Future Plans
- Table 45. Merck & Co Company Information, Head Office, and Major Competitors
- Table 46. Merck & Co Major Business
- Table 47. Merck & Co Therapeutic Antibodies Drug Product and Solutions
- Table 48. Merck & Co Therapeutic Antibodies Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 49. Merck & Co Recent Developments and Future Plans
- Table 50. Takeda Company Information, Head Office, and Major Competitors
- Table 51. Takeda Major Business
- Table 52. Takeda Therapeutic Antibodies Drug Product and Solutions
- Table 53. Takeda Therapeutic Antibodies Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 54. Takeda Recent Developments and Future Plans
- Table 55. Merck KGaA Company Information, Head Office, and Major Competitors
- Table 56. Merck KGaA Major Business
- Table 57. Merck KGaA Therapeutic Antibodies Drug Product and Solutions
- Table 58. Merck KGaA Therapeutic Antibodies Drug Revenue (USD Million), Gross

Margin and Market Share (2018-2023)

Table 59. Merck KGaA Recent Developments and Future Plans

Table 60. Seagen Company Information, Head Office, and Major Competitors

Table 61. Seagen Major Business

Table 62. Seagen Therapeutic Antibodies Drug Product and Solutions

Table 63. Seagen Therapeutic Antibodies Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 64. Seagen Recent Developments and Future Plans

Table 65. Eli Lilly Company Information, Head Office, and Major Competitors

Table 66. Eli Lilly Major Business

Table 67. Eli Lilly Therapeutic Antibodies Drug Product and Solutions

Table 68. Eli Lilly Therapeutic Antibodies Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 69. Eli Lilly Recent Developments and Future Plans

Table 70. Ono Pharmaceutical Company Information, Head Office, and Major Competitors

Table 71. Ono Pharmaceutical Major Business

Table 72. Ono Pharmaceutical Therapeutic Antibodies Drug Product and Solutions

Table 73. Ono Pharmaceutical Therapeutic Antibodies Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 74. Ono Pharmaceutical Recent Developments and Future Plans

Table 75. Pfizer Company Information, Head Office, and Major Competitors

Table 76. Pfizer Major Business

Table 77. Pfizer Therapeutic Antibodies Drug Product and Solutions

Table 78. Pfizer Therapeutic Antibodies Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 79. Pfizer Recent Developments and Future Plans

Table 80. Regeneron Company Information, Head Office, and Major Competitors

Table 81. Regeneron Major Business

Table 82. Regeneron Therapeutic Antibodies Drug Product and Solutions

Table 83. Regeneron Therapeutic Antibodies Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 84. Regeneron Recent Developments and Future Plans

Table 85. Innovent Company Information, Head Office, and Major Competitors

Table 86. Innovent Major Business

Table 87. Innovent Therapeutic Antibodies Drug Product and Solutions

Table 88. Innovent Therapeutic Antibodies Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 89. Innovent Recent Developments and Future Plans

- Table 90. Hengrui Medicine Company Information, Head Office, and Major Competitors
- Table 91. Hengrui Medicine Major Business
- Table 92. Hengrui Medicine Therapeutic Antibodies Drug Product and Solutions
- Table 93. Hengrui Medicine Therapeutic Antibodies Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 94. Hengrui Medicine Recent Developments and Future Plans
- Table 95. Global Therapeutic Antibodies Drug Revenue (USD Million) by Players (2018-2023)
- Table 96. Global Therapeutic Antibodies Drug Revenue Share by Players (2018-2023)
- Table 97. Breakdown of Therapeutic Antibodies Drug by Company Type (Tier 1, Tier 2, and Tier 3)
- Table 98. Market Position of Players in Therapeutic Antibodies Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
- Table 99. Head Office of Key Therapeutic Antibodies Drug Players
- Table 100. Therapeutic Antibodies Drug Market: Company Product Type Footprint
- Table 101. Therapeutic Antibodies Drug Market: Company Product Application Footprint
- Table 102. Therapeutic Antibodies Drug New Market Entrants and Barriers to Market Entry
- Table 103. Therapeutic Antibodies Drug Mergers, Acquisition, Agreements, and Collaborations
- Table 104. Global Therapeutic Antibodies Drug Consumption Value (USD Million) by Type (2018-2023)
- Table 105. Global Therapeutic Antibodies Drug Consumption Value Share by Type (2018-2023)
- Table 106. Global Therapeutic Antibodies Drug Consumption Value Forecast by Type (2024-2029)
- Table 107. Global Therapeutic Antibodies Drug Consumption Value by Application (2018-2023)
- Table 108. Global Therapeutic Antibodies Drug Consumption Value Forecast by Application (2024-2029)
- Table 109. North America Therapeutic Antibodies Drug Consumption Value by Type (2018-2023) & (USD Million)
- Table 110. North America Therapeutic Antibodies Drug Consumption Value by Type (2024-2029) & (USD Million)
- Table 111. North America Therapeutic Antibodies Drug Consumption Value by Application (2018-2023) & (USD Million)
- Table 112. North America Therapeutic Antibodies Drug Consumption Value by Application (2024-2029) & (USD Million)
- Table 113. North America Therapeutic Antibodies Drug Consumption Value by Country

(2018-2023) & (USD Million)

Table 114. North America Therapeutic Antibodies Drug Consumption Value by Country (2024-2029) & (USD Million)

Table 115. Europe Therapeutic Antibodies Drug Consumption Value by Type (2018-2023) & (USD Million)

Table 116. Europe Therapeutic Antibodies Drug Consumption Value by Type (2024-2029) & (USD Million)

Table 117. Europe Therapeutic Antibodies Drug Consumption Value by Application (2018-2023) & (USD Million)

Table 118. Europe Therapeutic Antibodies Drug Consumption Value by Application (2024-2029) & (USD Million)

Table 119. Europe Therapeutic Antibodies Drug Consumption Value by Country (2018-2023) & (USD Million)

Table 120. Europe Therapeutic Antibodies Drug Consumption Value by Country (2024-2029) & (USD Million)

Table 121. Asia-Pacific Therapeutic Antibodies Drug Consumption Value by Type (2018-2023) & (USD Million)

Table 122. Asia-Pacific Therapeutic Antibodies Drug Consumption Value by Type (2024-2029) & (USD Million)

Table 123. Asia-Pacific Therapeutic Antibodies Drug Consumption Value by Application (2018-2023) & (USD Million)

Table 124. Asia-Pacific Therapeutic Antibodies Drug Consumption Value by Application (2024-2029) & (USD Million)

Table 125. Asia-Pacific Therapeutic Antibodies Drug Consumption Value by Region (2018-2023) & (USD Million)

Table 126. Asia-Pacific Therapeutic Antibodies Drug Consumption Value by Region (2024-2029) & (USD Million)

Table 127. South America Therapeutic Antibodies Drug Consumption Value by Type (2018-2023) & (USD Million)

Table 128. South America Therapeutic Antibodies Drug Consumption Value by Type (2024-2029) & (USD Million)

Table 129. South America Therapeutic Antibodies Drug Consumption Value by Application (2018-2023) & (USD Million)

Table 130. South America Therapeutic Antibodies Drug Consumption Value by Application (2024-2029) & (USD Million)

Table 131. South America Therapeutic Antibodies Drug Consumption Value by Country (2018-2023) & (USD Million)

Table 132. South America Therapeutic Antibodies Drug Consumption Value by Country (2024-2029) & (USD Million)

Table 133. Middle East & Africa Therapeutic Antibodies Drug Consumption Value by Type (2018-2023) & (USD Million)

Table 134. Middle East & Africa Therapeutic Antibodies Drug Consumption Value by Type (2024-2029) & (USD Million)

Table 135. Middle East & Africa Therapeutic Antibodies Drug Consumption Value by Application (2018-2023) & (USD Million)

Table 136. Middle East & Africa Therapeutic Antibodies Drug Consumption Value by Application (2024-2029) & (USD Million)

Table 137. Middle East & Africa Therapeutic Antibodies Drug Consumption Value by Country (2018-2023) & (USD Million)

Table 138. Middle East & Africa Therapeutic Antibodies Drug Consumption Value by Country (2024-2029) & (USD Million)

Table 139. Therapeutic Antibodies Drug Raw Material

Table 140. Key Suppliers of Therapeutic Antibodies Drug Raw Materials

List Of Figures

LIST OF FIGURES

Figure 1. Therapeutic Antibodies Drug Picture

Figure 2. Global Therapeutic Antibodies Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029

Figure 3. Global Therapeutic Antibodies Drug Consumption Value Market Share by Type in 2022

Figure 4. Monoclonal Antibodies

Figure 5. Bi-Specific Antibodies Therapy

Figure 6. Antibody-drug Conjugates

Figure 7. Other

Figure 8. Global Therapeutic Antibodies Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029

Figure 9. Therapeutic Antibodies Drug Consumption Value Market Share by Application in 2022

Figure 10. Immune Diseases Picture

Figure 11. Cancer Picture

Figure 12. Other Picture

Figure 13. Global Therapeutic Antibodies Drug Consumption Value, (USD Million): 2018 & 2022 & 2029

Figure 14. Global Therapeutic Antibodies Drug Consumption Value and Forecast (2018-2029) & (USD Million)

Figure 15. Global Market Therapeutic Antibodies Drug Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)

Figure 16. Global Therapeutic Antibodies Drug Consumption Value Market Share by Region (2018-2029)

Figure 17. Global Therapeutic Antibodies Drug Consumption Value Market Share by Region in 2022

Figure 18. North America Therapeutic Antibodies Drug Consumption Value (2018-2029) & (USD Million)

Figure 19. Europe Therapeutic Antibodies Drug Consumption Value (2018-2029) & (USD Million)

Figure 20. Asia-Pacific Therapeutic Antibodies Drug Consumption Value (2018-2029) & (USD Million)

Figure 21. South America Therapeutic Antibodies Drug Consumption Value (2018-2029) & (USD Million)

Figure 22. Middle East and Africa Therapeutic Antibodies Drug Consumption Value

(2018-2029) & (USD Million)

Figure 23. Global Therapeutic Antibodies Drug Revenue Share by Players in 2022

Figure 24. Therapeutic Antibodies Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022

Figure 25. Global Top 3 Players Therapeutic Antibodies Drug Market Share in 2022

Figure 26. Global Top 6 Players Therapeutic Antibodies Drug Market Share in 2022

Figure 27. Global Therapeutic Antibodies Drug Consumption Value Share by Type (2018-2023)

Figure 28. Global Therapeutic Antibodies Drug Market Share Forecast by Type (2024-2029)

Figure 29. Global Therapeutic Antibodies Drug Consumption Value Share by Application (2018-2023)

Figure 30. Global Therapeutic Antibodies Drug Market Share Forecast by Application (2024-2029)

Figure 31. North America Therapeutic Antibodies Drug Consumption Value Market Share by Type (2018-2029)

Figure 32. North America Therapeutic Antibodies Drug Consumption Value Market Share by Application (2018-2029)

Figure 33. North America Therapeutic Antibodies Drug Consumption Value Market Share by Country (2018-2029)

Figure 34. United States Therapeutic Antibodies Drug Consumption Value (2018-2029) & (USD Million)

Figure 35. Canada Therapeutic Antibodies Drug Consumption Value (2018-2029) & (USD Million)

Figure 36. Mexico Therapeutic Antibodies Drug Consumption Value (2018-2029) & (USD Million)

Figure 37. Europe Therapeutic Antibodies Drug Consumption Value Market Share by Type (2018-2029)

Figure 38. Europe Therapeutic Antibodies Drug Consumption Value Market Share by Application (2018-2029)

Figure 39. Europe Therapeutic Antibodies Drug Consumption Value Market Share by Country (2018-2029)

Figure 40. Germany Therapeutic Antibodies Drug Consumption Value (2018-2029) & (USD Million)

Figure 41. France Therapeutic Antibodies Drug Consumption Value (2018-2029) & (USD Million)

Figure 42. United Kingdom Therapeutic Antibodies Drug Consumption Value (2018-2029) & (USD Million)

Figure 43. Russia Therapeutic Antibodies Drug Consumption Value (2018-2029) &

(USD Million)

Figure 44. Italy Therapeutic Antibodies Drug Consumption Value (2018-2029) & (USD Million)

Figure 45. Asia-Pacific Therapeutic Antibodies Drug Consumption Value Market Share by Type (2018-2029)

Figure 46. Asia-Pacific Therapeutic Antibodies Drug Consumption Value Market Share by Application (2018-2029)

Figure 47. Asia-Pacific Therapeutic Antibodies Drug Consumption Value Market Share by Region (2018-2029)

Figure 48. China Therapeutic Antibodies Drug Consumption Value (2018-2029) & (USD Million)

Figure 49. Japan Therapeutic Antibodies Drug Consumption Value (2018-2029) & (USD Million)

Figure 50. South Korea Therapeutic Antibodies Drug Consumption Value (2018-2029) & (USD Million)

Figure 51. India Therapeutic Antibodies Drug Consumption Value (2018-2029) & (USD Million)

Figure 52. Southeast Asia Therapeutic Antibodies Drug Consumption Value (2018-2029) & (USD Million)

Figure 53. Australia Therapeutic Antibodies Drug Consumption Value (2018-2029) & (USD Million)

Figure 54. South America Therapeutic Antibodies Drug Consumption Value Market Share by Type (2018-2029)

Figure 55. South America Therapeutic Antibodies Drug Consumption Value Market Share by Application (2018-2029)

Figure 56. South America Therapeutic Antibodies Drug Consumption Value Market Share by Country (2018-2029)

Figure 57. Brazil Therapeutic Antibodies Drug Consumption Value (2018-2029) & (USD Million)

Figure 58. Argentina Therapeutic Antibodies Drug Consumption Value (2018-2029) & (USD Million)

Figure 59. Middle East and Africa Therapeutic Antibodies Drug Consumption Value Market Share by Type (2018-2029)

Figure 60. Middle East and Africa Therapeutic Antibodies Drug Consumption Value Market Share by Application (2018-2029)

Figure 61. Middle East and Africa Therapeutic Antibodies Drug Consumption Value Market Share by Country (2018-2029)

Figure 62. Turkey Therapeutic Antibodies Drug Consumption Value (2018-2029) & (USD Million)

Figure 63. Saudi Arabia Therapeutic Antibodies Drug Consumption Value (2018-2029) & (USD Million)

Figure 64. UAE Therapeutic Antibodies Drug Consumption Value (2018-2029) & (USD Million)

Figure 65. Therapeutic Antibodies Drug Market Drivers

Figure 66. Therapeutic Antibodies Drug Market Restraints

Figure 67. Therapeutic Antibodies Drug Market Trends

Figure 68. Porters Five Forces Analysis

Figure 69. Manufacturing Cost Structure Analysis of Therapeutic Antibodies Drug in 2022

Figure 70. Manufacturing Process Analysis of Therapeutic Antibodies Drug

Figure 71. Therapeutic Antibodies Drug Industrial Chain

Figure 72. Methodology

Figure 73. Research Process and Data Source

I would like to order

Product name: Global Therapeutic Antibodies Drug Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Product link: <https://marketpublishers.com/r/G8956600C324EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G8956600C324EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

